Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK settles antidepressant patent dispute
<p>The original litigation related to Andrx Corporation which Watson acquired for $1.9 billion in 2006. <br /><br />In 2005, Andrx Corporation filed a patent infringement lawsuit in a
<p>The original litigation related to Andrx Corporation which Watson acquired for $1.9 billion in 2006. <br /><br />In 2005, Andrx Corporation filed a patent infringement lawsuit in a
The researchers report that a compound that was frequently used to treat high blood pressure can reverse iron overload in mouse models and has the potential to treat
Previous research had identified that increased levels and actions of the enzyme, AMPK, as a control lever for appetite. Suspecting that antipsychotic drugs might spike AMPK in the
AMDL said its subsidiary’s sales network is uniquely positioned to take advantage of the significant marketing opportunity in China. Docetaxel is an anticancer drug that interferes with the
The agency has determined that the balance of benefits and risks no longer support approval of the drug for these indications. Ketek will remain on the market for
Gail Schulze president of YM BioSciences and CEO of YM BioSciences USA, and John Bennett vice president of Corporate Development at YM BioSciences USA, have left their positions.
“Pharmaceutical companies and regulatory agencies need to bring the cutting-edge benefits of biotech drugs to patients as quickly, safely and at the lowest cost possible,” said CTI's president
The re-focused pharmaceutical development program will concentrate on the FM-TP series of compounds targeting metabolic syndrome and its underlying disease states such as diabetes, the systemic inflammation that
The phase I study is designed to investigate the safety, tolerability and pharmacokinetics of ADL5859 in healthy volunteers following twice a day dosing for seven days. This study
The takeover would have created the largest pharmaceutical company in the world, overtaking Pfizer. The talks are believed to have collapsed because of the French drug maker's objection